A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

被引：0
|
作者：
Alison M. Schram
Leena Gandhi
Monica M. Mita
Lars Damstrup
Frank Campana
Manuel Hidalgo
Enrique Grande
David M. Hyman
Rebecca S. Heist
机构：
[1] Memorial Sloan Kettering Cancer Center,
[2] New York University Perlmutter Cancer Center,undefined
[3] Cedars-Sinai Medical Center,undefined
[4] Merck Serono,undefined
[5] Sanofi-Aventis,undefined
[6] Beth Israel Deaconess Medical Center,undefined
[7] Hospital Universitario Ramon y Cajal,undefined
[8] Massachusetts General Hospital,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1471 / 1476
页数：5
相关论文
共 50 条
  • [41] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
  • [42] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer (vol 46, pg 837, 2020)
    Kondo, Shunsuke
    Tajimi, Masaomi
    Funai, Tomohiko
    Inoue, Koichi
    Asou, Hiroya
    Ranka, Vinay Kumar
    Wacheck, Volker
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1846 - 1846
  • [43] PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR IPATASERTIB (IPAT) WITH PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Isakoff, S. J.
    Infante, J. R.
    Juric, D.
    Chan, W. Y.
    Jia, S.
    Musib, L.
    Zhu, J.
    Meng, R.
    Patel, P. H.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [44] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
    Calvo, E.
    Edelman, G.
    Baselga, J.
    Kwak, E.
    Scheffold, C.
    Nguyen, L.
    Shapiro, G. I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [45] Phase Ⅰ dose-escalation and expansion study of PARP inhibitor,fluzoparib(SHR3162), in patients with advanced solid tumors
    Huiping Li
    Rongrui Liu
    Bin Shao
    Ran Ran
    Guohong Song
    Ke Wang
    Yehui Shi
    Jihong Liu
    Wenjing Hu
    Fu Chen
    Xiaoran Liu
    Gairong Zhang
    Chuanhua Zhao
    Ru Jia
    Quanren Wang
    Hope S.Rugo
    Yifan Zhang
    Guangze Li
    Jianming Xu
    Chinese Journal of Cancer Research, 2020, 32 (03) : 370 - 384
  • [46] Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey Alan
    Pavlick, Anna C.
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
    Wilson, R.
    Dass, P. Hari
    Van Schaeybroeck, S.
    Elez Fernandez, E.
    Jones, R.
    Quinton, A.
    Houlden, J.
    Collins, L.
    Roberts, C.
    Love, S.
    Lawler, M.
    Di Nicolantonio, F.
    Grayson, M.
    Bardelli, A.
    Laurent-Puig, P.
    Maughan, T.
    Tabernero, J.
    Peeters, M.
    Middleton, M.
    Rolfo, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E140 - E141
  • [48] Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.
    Wang, Huaqing
    Jiang, Wenqi
    Li, Su
    Wang, Yu
    Sun, Peng
    Zhou, Pei
    Zheng, Yang
    Zhan, Jing
    Li, Zhiming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
    Kristeleit, Rebecca Sophie
    Brown, Nicholas F.
    Hess, Dagmar
    Joerger, Markus
    Von Moos, Roger
    Rodon, Jordi
    Hierro, Cinta
    Childs, Alexa
    Stathis, Anastasios
    Dimitrijevic, Sasa
    Stumm, Michael
    Herrmann, Richard
    Sessa, Cristiana
    Bize, Vincent
    Hess, Viviane
    Wicki, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
    van Herpen, C. M. L.
    Eskens, F. A. L. M.
    de Jonge, M.
    Desar, I.
    Hooftman, L.
    Bone, E. A.
    Timmer-Bonte, J. N. H.
    Verweij, J.
    BRITISH JOURNAL OF CANCER, 2010, 103 (09) : 1362 - 1368
12345